Loading
A 17-gene biopsy test that helps men with newly diagnosed low-risk prostate cancer decide whether to watch or treat.
Developed by Genomic Health and sold by Exact Sciences until MDxHealth acquired the test in 2022, the Genomic Prostate Score predicts adverse pathology at prostatectomy and long-term metastasis and death, validated in surgical cohorts and in the Kaiser Permanente and Veterans Affairs populations. NCCN lists it for very-low to favourable-intermediate risk disease. In practice it is ordered when a man and his urologist are on the fence about active surveillance. As with Prolaris and Decipher, evidence that the test changes long-term outcomes rather than decisions is lacking.
RT-PCR of 12 cancer genes across four pathways (androgen signalling, proliferation, cellular organisation, stromal response) and five reference genes on biopsy tissue, giving a 0-100 Genomic Prostate Score.
1.Oncotype DX Genomic Prostate Score slips into a pocket on its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Oncotype DX Genomic Prostate Score" OR ABSTRACT:"Oncotype DX Genomic Prostate Score" OR TITLE:"Oncotype DX GPS" OR ABSTRACT:"Oncotype DX GPS") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Oncotype DX Genomic Prostate Score, not a curated reading list.
Shares RNA sequencing & expression profiling and the tag test.
Shares RNA sequencing & expression profiling and the tag test.
Shares RNA sequencing & expression profiling and the tag test.
Shares RNA sequencing & expression profiling and the tag test.
Shares Prostate cancer and the tag test.
Shares RNA sequencing & expression profiling and the tag test.
Shares RNA sequencing & expression profiling and the tag test.
Shares Prostate cancer and the tag test.